Trospium chloride

An ordinary bladder drug that turned out to be the cleverest component in a landmark psychiatric medicine, and for a reason that has nothing to do with the bladder. Its value in Cobenfy is a negative property: a permanent positive charge that keeps it out of the brain. Judged as a bladder drug alone it is unremarkable and fiddly to dose. Judged as a piece of drug design it is one of the better ideas in modern pharmacology.

Alone, trospium produces the expected peripheral antimuscarinic effects: dry mouth, constipation, blurred vision and urinary retention, the last of which becomes a contraindication rather than a side effect in anyone already retaining urine. It is not metabolised through cytochrome P450, relying instead on ester hydrolysis and glucuronidation, so it carries few metabolic interactions; renal impairment does raise exposure and the immediate release dose is cut to once daily below a creatinine clearance of 30 mL/min.

The cognitive impairment associated with brain penetrant anticholinergics such as oxybutynin has not appeared in the studies that specifically looked for it with trospium, and one of those studies measured cerebrospinal fluid directly rather than inferring it ^[1]. Inside Cobenfy, trospium is what puts urinary retention, gastric retention and reduced gut motility on the combined product's contraindication and warning list ^[3].

Trospium chloride is an old European drug; it has been used for overactive bladder since the 1990s and was approved in the United States in 2004 as Sanctura, with an extended release form following. Its second life came from Karuna Therapeutics, which needed a peripheral muscarinic blocker to make xanomeline tolerable and chose trospium precisely because it had already been shown not to reach the brain. That pairing became KarXT, and the FDA approved it as Cobenfy on 26 September 2024. It is an unusual example of a generic drug being repurposed not for its own therapeutic effect but as a chemical shield for another molecule.

Among urologists it has long been the antimuscarinic of choice when cognitive safety matters, particularly in older patients, on the strength of the cerebrospinal fluid work. Outside urology it was almost unknown until Cobenfy, and it is now routinely mentioned in psychiatric coverage as the reason a 1990s failure became a 2024 approval.